ClinicalTrials.gg
Not yet recruitingNCT07948967NIV-EFIUpdated Nov 19, 2026

Physiological Associations and Prognostic Discrimination of an EIT-Derived Flow Index During Noninvasive Ventilation

An observational study in Acute Hypoxemic Respiratory Failure and Noninvasive Ventilation, sponsored by Ruijin Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Ruijin Hospital · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
220
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 93 studies in Respiratory Insufficiency with a site in China — 30 open to participants now, 30 under way, 1 of them phase 3. Respiratory Insufficiency · China.

Planned enrollment
16th of 36
220 · median 175
Started
2026
with 6 others
Observational
36 of 93
12 open now
Primary completion
2028-09
later than 26 of 29 live
Registered
93rd of 93
by date
Lead sponsor
5 of 93
Ruijin Hospital

Among the 93 studies in Respiratory Insufficiency with a site in China, this one is the 16th largest by planned enrollment of the 36 observational ones that give a count, is one of 7 that started in 2026, is one of 36 observational ones, reaches primary completion later than 26 of the 29 other live ones, and was the 93rd registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 265 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

30 of the 93 studies in Respiratory Insufficiency with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Respiratory Insufficiency with a site in China, or all of them as a file.
02

Study summary

This is a multicenter prospective observational cohort study with a nested physiological substudy. It aims to enroll 220 adults with acute hypoxemic respiratory failure (AHRF) initiating mask noninvasive ventilation (NIV). The study will assess the measurement feasibility, physiological associations, and early prognostic discrimination of the electrical impedance tomography (EIT)-derived flow index (EFI) during NIV. The primary objective is to estimate how well pre-landmark T1 EFI discriminates the risk of endotracheal intubation or all-cause death through 48 hours. A nested physiological substudy (n=20) will evaluate the within-patient association between EFI and airway occlusion pressure across fixed pressure support (PS) levels (5, 10, and 15 cmH2O). Clinical management remains independent of study measurements.

Read the detailed description

This study will enroll adults with AHRF for whom the treating team has decided to initiate mask NIV. The main cohort (n=220) is observational. EIT data will be acquired at baseline (T0), 60-120 min (T1), 20-24 h (T2), and 42-48 h (T3). The primary predictor is the median EFI across valid breaths during T1 (before the 2-h landmark). The primary endpoint is the first occurrence of endotracheal intubation or all-cause death after 2 h and through 48 h among patients eligible at the 2-h landmark.

A nested, non-randomized physiological substudy (n=20) will be conducted after T1. After confirming safety and obtaining separate informed consent, patients will undergo a fixed sequence of brief pressure support steps (PS 5, 10, and 15 cmH2O) with EPAP and FiO2 held at clinical settings. Brief airway occlusions will be performed at each level to measure occlusion pressure (Pocc and P0.1). The substudy aims to estimate the within-patient association between EFI and \|Pocc\|. The study was approved by the Ethics Committee of Ruijin Hospital (Approval No. 2026846). Written informed consent is obtained from all participants (and separate consent for the substudy).

03

Conditions studied

  • Acute Hypoxemic Respiratory Failure
  • Noninvasive Ventilation

Keywords

  • Electrical Impedance Tomography
  • EIT-derived Flow Index
  • Noninvasive Ventilation
  • Acute Hypoxemic Respiratory Failure
  • Prognostic Discrimination; Respiratory Drive
  • Airway Occlusion Pressure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults (aged 18 years or older) with acute hypoxemic respiratory failure (AHRF) for whom the treating clinical team has decided to initiate mask noninvasive ventilation (NIV) in the intensive care unit. A subset of stable patients will participate in the nested physiological sub-study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Clinical diagnosis of AHRF and a decision to initiate NIV through an oronasal or full-face mask (PaO2/FiO2 ≤ 300 mmHg or FiO2 ≥ 0.40 to maintain oxygenation target).
  • Consent and enrollment completed before NIV begins or within 60 min of initiation.
  • Written from the patient or authorized representative (separate consent for substudy).

Exclusion criteria

Exclusion Criteria:

  • Immediate clinical need for endotracheal intubation or clear to NIV.
  • Facial trauma, severe chest-wall skin injury, or incisions preventing safe placement of EIT belt.
  • Contraindication in EIT device manual (e.g., incompatible implanted device).
  • Pregnancy or lactation.
  • Baseline do-not-intubate (DNI) decision or comfort measures only.
  • Inability to obtain valid consent.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
220 participants (estimated)
Patient registry
No

Groups and cohorts

  • Main Cohort

    Adults with AHRF initiating mask NIV (n=220). Observational; T1 EFI is evaluated for discriminating 48-hour intubation or death.

    Other: Noninvasive Ventilation (NIV) · Device: Electrical Impedance Tomography (EIT) Monitoring

  • Nested Physiological Substudy

    A subset of the main cohort (n=20). Consenting patients undergo brief, sequential pressure support (PS) adjustments (5, 10, 15 cmH2O) and airway occlusions to measure EFI and \|Pocc\| associations.

    Other: Noninvasive Ventilation (NIV) · Device: Electrical Impedance Tomography (EIT) Monitoring · Other: Brief Pressure Support Adjustment and Airway Occlusion (Substudy only)

Interventions

  • OtherNoninvasive Ventilation (NIV)

    Standard clinical care through oronasal or full-face mask. Settings are directed by the treating team.

  • DeviceElectrical Impedance Tomography (EIT) Monitoring

    Continuous EIT monitoring to derive the dimensionless flow index (EFI).

  • OtherBrief Pressure Support Adjustment and Airway Occlusion (Substudy only)

    Protocol-specified PS steps (5, 10, 15 cmH2O) and device-supported airway occlusions performed in the physiological substudy.

06

What researchers measure

Primary outcomes

  1. Incidence of Endotracheal Intubation or All-Cause Death (2h to 48h)

    The first occurrence of endotracheal intubation or all-cause death after 2 hours and through 48 hours from NIV initiation, among patients alive and still receiving NIV at the 2-hour landmark.Unit of Measure: Proportion of participants (or Event count)

    Time frame: After 2 hours through 48 hours.

Secondary outcomes

  1. Discrimination Performance (AUC) of T1 EFI

    Area under the receiver operating characteristic curve (AUC) of the pre-landmark T1 EFI for predicting the primary composite endpoint.Unit of Measure: AUC (dimensionless, 0-1)

    Time frame: Within 72 hours

  2. Within-Patient Association between EFI and |Pocc|

    The within-patient slope of the association between EFI and the absolute magnitude of occlusion pressure (\|Pocc\|) across fixed pressure support levels in the physiological sub-study. Unit of Measure: cmH2O per unit of EFI

    Time frame: Within 2 to 6 hours after NIV initiation.

  3. Intubation or Death by Day 7

    ncidence of endotracheal intubation or all-cause mortality by day 7.Unit of Measure: Proportion of participants

    Time frame: Within day 7

  4. 28-Day All-Cause Mortality

    All-cause mortality rate at day 28.Unit of Measure: Proportion of participants

    Time frame: within day 28

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — De-identified analysis datasets may be shared on reasonable request for verification, subject to ethics approval.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Sep 2028, 21 months later.

Of 232 non-industry observational studies under Respiratory Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's planned 21 months is close to that.

Counting every sponsor, half of 248 studies reached it within 22 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948967
Lead sponsor
Ruijin Hospital
Collaborators
Shanghai East Hospital, Zhoukou Central Hospital, The First Affiliated Hospital of Soochow University
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Sep 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Rui Zhang
Contact
ccmzhangrui@foxmail.com
+86-18801119381

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion